2PU Stock Overview
A clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Pulmatrix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.09 |
| 52 Week High | US$9.45 |
| 52 Week Low | US$1.56 |
| Beta | 1.38 |
| 1 Month Change | 31.78% |
| 3 Month Change | -2.88% |
| 1 Year Change | 332.32% |
| 3 Year Change | 56.17% |
| 5 Year Change | -75.31% |
| Change since IPO | -98.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2PU | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 22.9% | 1.1% | 1.1% |
| 1Y | 332.3% | -25.0% | 16.3% |
Return vs Industry: 2PU exceeded the German Pharmaceuticals industry which returned -24.4% over the past year.
Return vs Market: 2PU exceeded the German Market which returned 16.4% over the past year.
Price Volatility
| 2PU volatility | |
|---|---|
| 2PU Average Weekly Movement | 13.2% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 2PU's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2PU's weekly volatility has decreased from 19% to 13% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2 | Peter Ludlum | www.pulmatrix.com |
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.
Pulmatrix, Inc. Fundamentals Summary
| 2PU fundamental statistics | |
|---|---|
| Market cap | €26.38m |
| Earnings (TTM) | -€10.74m |
| Revenue (TTM) | €1.69m |
Is 2PU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2PU income statement (TTM) | |
|---|---|
| Revenue | US$1.92m |
| Cost of Revenue | US$149.00k |
| Gross Profit | US$1.77m |
| Other Expenses | US$13.96m |
| Earnings | -US$12.19m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.34 |
| Gross Margin | 92.24% |
| Net Profit Margin | -634.67% |
| Debt/Equity Ratio | 0% |
How did 2PU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/30 09:50 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pulmatrix, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Dawson James Securities |
| Andrew Fein | H.C. Wainwright & Co. |
| Anita Dushyanth | Zacks Investment Research Inc. |